OPKO Health stock gets Zacks upgrade while shares fall 4.79 percent

Published on 10/08/2026 at 05:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

OPKO Health stock stood at USD 1.390 on Nasdaq on October 7, below its USD 1.750 52-week high. Q2 revenue rose 4.3 percent to USD 163.58 million.

OPK, US68375N1037, Illustration mit AI erstellt.

OPKO Health stock (ISIN US68375N1037) fell 4.79 percent to USD 1.390 on Nasdaq on October 7, 2026, after trading between USD 1.375 and USD 1.430. The latest analyst action came on September 30, 2026, when Zacks Research upgraded the stock from Hold to Strong Buy, according to MarketBeat.

Zacks raises the rating

The upgrade adds a bullish analyst view to a stock that remains below its recent yearly peak. MarketBeat reports that the broader analyst consensus was Hold, based on one Strong Buy, one Buy, three Hold ratings and one Sell rating on September 30, 2026.

The rating change is separate from the latest session move. OPK finished October 7 at USD 1.390, while its 52-week range stood at USD 0.977 to USD 1.750.

Q2 revenue rose 4.3 percent

OPKO's latest reported quarter provided the operating comparison behind much of the current debate. In Q2 2026, revenue reached USD 163.58 million, up 4.3 percent from the same quarter a year earlier, while adjusted loss per share was USD 0.01 versus a consensus loss of USD 0.08, according to MarketBeat.

The finance statement for June 30, 2026, shows a net loss attributable to common shareholders of USD 8.416 million and operating cash flow of negative USD 43.5 million. The figures keep the revenue improvement in perspective because profitability and cash generation remained important counterweights.

Target sits above the share price

MarketBeat lists an average price target of USD 1.55, a high target of USD 1.60 and a low target of USD 1.50. Its Hold consensus covers five ratings, while the average target lies 11.5 percent above the October 7 price of USD 1.390.

At the October 7 close, OPKO had a market capitalization of USD 1.0 billion and volume of 2,223,181 shares. The stock's position below the USD 1.750 yearly high leaves the analyst upgrade competing with a clear one-session decline.

OPKO Health stock remains below its yearly high

OPKO Health stock finished at USD 1.390 on Nasdaq on October 7, 2026, with a 52-week range of USD 0.977 to USD 1.750. The rating change, Q2 revenue growth and ongoing loss profile now define the main figures for investors assessing the company.